Swiss National Bank Vertex Pharmaceuticals Inc Transaction History

Swiss National Bank

$143 Billion
Q2 2024

A detailed history of Swiss National Bank transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Swiss National Bank holds 764,800 shares of VRTX stock, worth $363 Million. This represents 0.25% of its overall portfolio holdings.

Number of Shares

764,800

Previous 771,700 0.89%

Holding current value

$363 Million

Previous $323 Million 11.13%

% of portfolio

0.25%

Previous 0.23%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$392.81 - $485.53 $2.71 Million - $3.35 Million	-6,900 Reduced 0.89%	764,800 $358 Million
Q1 2024 May 07, 2024	SELL	$407.69 - $446.08 $14.4 Million - $15.8 Million	-35,400 Reduced 4.39%	771,700 $323 Million
Q4 2023 Feb 06, 2024	SELL	$343.0 - $410.68 $7.31 Million - $8.75 Million	-21,300 Reduced 2.57%	807,100 $328 Million
Q3 2023 Nov 08, 2023	SELL	$338.18 - $362.46 $34.5 Million - $36.9 Million	-101,900 Reduced 10.95%	828,400 $288 Million
Q2 2023 Aug 09, 2023	SELL	$314.42 - $351.91 $27.8 Million - $31.1 Million	-88,500 Reduced 8.69%	930,300 $327 Million
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $6.68 Million - $7.63 Million	-23,600 Reduced 2.26%	1,018,800 $321 Million
Q4 2022 Feb 08, 2023	SELL	$285.76 - $321.48 $18.9 Million - $21.2 Million	-65,975 Reduced 5.95%	1,042,400 $301 Million
Q3 2022 Nov 09, 2022	BUY	$273.83 - $305.53 $1.12 Million - $1.25 Million	4,100 Added 0.37%	1,108,375 $321 Million
Q2 2022 Aug 09, 2022	BUY	$234.96 - $292.55 $728,376 - $906,905	3,100 Added 0.28%	1,104,275 $311 Million
Q1 2022 May 09, 2022	BUY	$221.42 - $260.97 $25.5 Million - $30 Million	115,100 Added 11.67%	1,101,175 $287 Million
Q4 2021 Feb 08, 2022	SELL	$177.01 - $223.45 $6.66 Million - $8.4 Million	-37,600 Reduced 3.67%	986,075 $217 Million
Q3 2021 Nov 08, 2021	SELL	$181.39 - $202.99 $6.58 Million - $7.37 Million	-36,300 Reduced 3.42%	1,023,675 $186 Million
Q2 2021 Aug 06, 2021	SELL	$187.49 - $221.1 $80.4 Million - $94.9 Million	-429,000 Reduced 28.81%	1,059,975 $214 Million
Q1 2021 May 07, 2021	BUY	$207.02 - $241.31 $4.45 Million - $5.19 Million	21,500 Added 1.47%	1,488,975 $320 Million
Q4 2020 Feb 05, 2021	BUY	$207.01 - $276.09 $16 Million - $21.3 Million	77,300 Added 5.56%	1,467,475 $347 Million
Q3 2020 Nov 09, 2020	BUY	$255.65 - $303.1 $52.3 Million - $62 Million	204,400 Added 17.24%	1,390,175 $378 Million
Q2 2020 Aug 05, 2020	BUY	$225.48 - $295.8 $33.8 Million - $44.3 Million	149,700 Added 14.45%	1,185,775 $344 Million
Q1 2020 May 08, 2020	BUY	$199.77 - $247.81 $41.1 Million - $51 Million	205,900 Added 24.8%	1,036,075 $247 Million
Q4 2019 Feb 06, 2020	SELL	$166.71 - $223.91 $5.8 Million - $7.79 Million	-34,800 Reduced 4.02%	830,175 $182 Million
Q3 2019 Nov 12, 2019	BUY	$166.23 - $187.09 $1.81 Million - $2.03 Million	10,866 Added 1.27%	864,975 $147 Million
Q2 2019 Aug 02, 2019	BUY	$164.61 - $190.37 $197,532 - $228,444	1,200 Added 0.14%	854,109 $157 Million
Q1 2019 May 10, 2019	BUY	$163.73 - $194.7 $3.6 Million - $4.28 Million	22,000 Added 2.65%	852,909 $157 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $2.64 Million - $3.34 Million	17,400 Added 2.14%	830,909 $138 Million
Q3 2018 Nov 08, 2018	SELL	$167.73 - $192.74 $4.24 Million - $4.88 Million	-25,300 Reduced 3.02%	813,509 $157 Million
Q2 2018 Aug 09, 2018	BUY	$145.72 - $169.96 $3.99 Million - $4.66 Million	27,400 Added 3.38%	838,809 $143 Million
Q1 2018 May 04, 2018	SELL	$151.6 - $177.13 $17.8 Million - $20.8 Million	-117,600 Reduced 12.66%	811,409 $132 Million
Q4 2017 Feb 07, 2018	BUY	$137.28 - $155.55 $1.48 Million - $1.68 Million	10,800 Added 1.18%	929,009 $139 Million
Q3 2017 Nov 03, 2017	BUY	$148.13 - $162.24 $136 Million - $149 Million	918,209	918,209 $140 Million

Others Institutions Holding VRTX

# of Institutions

1,707

Shares Held

226M

Call Options Held

1.2M

Put Options Held

1.59M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Vertex Pharmaceuticals Inc Transaction History